Currently out of the existing stock ratings of Nick Abbott, 5 are a HOLD (62.5%), 3 are a BUY (37.5%).

Nick Abbott

Work Performance Price Targets & Ratings Chart

Analyst Nick Abbott, currently employed carries an average stock price target met ratio of 47.22% that have a potential upside of 35.01% achieved within 200 days.

Nick Abbott’s has documented 17 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on IOVA, Iovance Biotherapeutics at 30-May-2023.

Wall Street Analyst Nick Abbott

Analyst best performing recommendations are on MRNA (MODERNA).
The best stock recommendation documented was for MRNA (MODERNA) at 8/13/2021. The price target of $145 was fulfilled within 185 days with a profit of $244.78 (62.8%) receiving and performance score of 3.39.

Average potential price target upside

MRNA Moderna AFMD Affimed NV FATE Fate Therapeutics IOVA Iovance Biotherapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

$41

$-0.83 (-1.98%)

$110

10 days ago
(10-Dec-2024)

19/22 (86.36%)

$-3.02 (-6.86%)

173

5.67

Sell

$45

$3.17 (7.58%)

$59

24 days ago
(26-Nov-2024)

7/8 (87.5%)

$2.64 (6.23%)

45

4.72

Buy

$69

$27.17 (64.95%)

$115

1 months 2 days ago
(18-Nov-2024)

39/55 (70.91%)

$30.5 (79.22%)

77

8.77

Buy

$111

$69.17 (165.36%)

$125

1 months 12 days ago
(08-Nov-2024)

8/12 (66.67%)

$63.02 (131.35%)

74

5.81

Buy

$108

$66.17 (158.19%)

$151

1 months 26 days ago
(24-Oct-2024)

2/6 (33.33%)

$55.2 (104.55%)

106

3.58

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Nick Abbott?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?